JPS63166825A - Clear gel drug preparation containing urea in stable state - Google Patents
Clear gel drug preparation containing urea in stable stateInfo
- Publication number
- JPS63166825A JPS63166825A JP31466486A JP31466486A JPS63166825A JP S63166825 A JPS63166825 A JP S63166825A JP 31466486 A JP31466486 A JP 31466486A JP 31466486 A JP31466486 A JP 31466486A JP S63166825 A JPS63166825 A JP S63166825A
- Authority
- JP
- Japan
- Prior art keywords
- urea
- water
- added
- base
- carboxyvinyl polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title claims abstract description 58
- 239000004202 carbamide Substances 0.000 title claims abstract description 58
- 238000002360 preparation method Methods 0.000 title abstract description 25
- 239000003814 drug Substances 0.000 title abstract description 11
- 229940079593 drug Drugs 0.000 title abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 35
- 239000000203 mixture Substances 0.000 claims abstract description 22
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 18
- 150000005846 sugar alcohols Polymers 0.000 claims abstract description 9
- 239000003002 pH adjusting agent Substances 0.000 claims abstract description 5
- 238000009472 formulation Methods 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract description 21
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 abstract description 6
- 239000004475 Arginine Substances 0.000 abstract description 3
- 206010012438 Dermatitis atopic Diseases 0.000 abstract description 3
- 206010020649 Hyperkeratosis Diseases 0.000 abstract description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract description 3
- 201000008937 atopic dermatitis Diseases 0.000 abstract description 3
- 239000002537 cosmetic Substances 0.000 abstract description 3
- 150000007530 organic bases Chemical class 0.000 abstract description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract description 2
- 206010048218 Xeroderma Diseases 0.000 abstract description 2
- 206010021198 ichthyosis Diseases 0.000 abstract description 2
- 230000000638 stimulation Effects 0.000 abstract 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 20
- 239000000243 solution Substances 0.000 description 18
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 10
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 10
- 229960002216 methylparaben Drugs 0.000 description 10
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 10
- 235000011187 glycerol Nutrition 0.000 description 9
- 239000006071 cream Substances 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- -1 etc.1 indomexin Chemical compound 0.000 description 5
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 5
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 5
- 229960003415 propylparaben Drugs 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 3
- 229940043276 diisopropanolamine Drugs 0.000 description 3
- 239000003349 gelling agent Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000001126 Keratosis Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- SLINHMUFWFWBMU-UHFFFAOYSA-N Triisopropanolamine Chemical compound CC(O)CN(CC(C)O)CC(C)O SLINHMUFWFWBMU-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- LLEMOWNGBBNAJR-UHFFFAOYSA-N biphenyl-2-ol Chemical compound OC1=CC=CC=C1C1=CC=CC=C1 LLEMOWNGBBNAJR-UHFFFAOYSA-N 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- XFOQWQKDSMIPHT-UHFFFAOYSA-N 2,3-dichloro-6-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(Cl)C(Cl)=N1 XFOQWQKDSMIPHT-UHFFFAOYSA-N 0.000 description 1
- XULHFMYCBKQGEE-UHFFFAOYSA-N 2-hexyl-1-Decanol Chemical compound CCCCCCCCC(CO)CCCCCC XULHFMYCBKQGEE-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- WADQOGCINABPRT-UHFFFAOYSA-N 3-chloro-2-methylphenol Chemical compound CC1=C(O)C=CC=C1Cl WADQOGCINABPRT-UHFFFAOYSA-N 0.000 description 1
- DQYSALLXMHVJAV-UHFFFAOYSA-M 3-heptyl-2-[(3-heptyl-4-methyl-1,3-thiazol-3-ium-2-yl)methylidene]-4-methyl-1,3-thiazole;iodide Chemical compound [I-].CCCCCCCN1C(C)=CS\C1=C\C1=[N+](CCCCCCC)C(C)=CS1 DQYSALLXMHVJAV-UHFFFAOYSA-M 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 1
- 241000287227 Fringillidae Species 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 150000003868 ammonium compounds Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004703 clobetasol propionate Drugs 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 description 1
- 229960003338 crotamiton Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- 229940031569 diisopropyl sebacate Drugs 0.000 description 1
- XFKBBSZEQRFVSL-UHFFFAOYSA-N dipropan-2-yl decanedioate Chemical compound CC(C)OC(=O)CCCCCCCCC(=O)OC(C)C XFKBBSZEQRFVSL-UHFFFAOYSA-N 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 239000004318 erythorbic acid Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229960000192 felbinac Drugs 0.000 description 1
- 229960000785 fluocinonide Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- QAKXLTNAJLFSQC-UHFFFAOYSA-N hexadecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC QAKXLTNAJLFSQC-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical group CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- WORCCYVLMMTGFR-UHFFFAOYSA-M loxoprofen sodium Chemical compound [Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 WORCCYVLMMTGFR-UHFFFAOYSA-M 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000010292 orthophenyl phenol Nutrition 0.000 description 1
- 239000004306 orthophenyl phenol Substances 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- BORJONZPSTVSFP-UHFFFAOYSA-N tetradecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCCCOC(=O)C(C)O BORJONZPSTVSFP-UHFFFAOYSA-N 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229960004880 tolnaftate Drugs 0.000 description 1
- FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
Abstract
Description
【発明の詳細な説明】
(イ)産業上の利用分野
本発明は尿素を安定に含有する透明ゲル製剤に関するも
のである。更に詳しくは、尿素を有効成分として含有し
、尿素の安定性をよくした透明ゲル製剤に関するもので
ある。尿素は保湿作用、蛋白融解変性作用、抗菌作用等
の薬理作用を有しており、尿素を配合した外用製剤はア
トピー性湿疹。DETAILED DESCRIPTION OF THE INVENTION (a) Field of Industrial Application The present invention relates to a transparent gel preparation stably containing urea. More specifically, the present invention relates to a transparent gel preparation that contains urea as an active ingredient and has improved stability of urea. Urea has pharmacological effects such as moisturizing, proteolytic and denaturing, and antibacterial effects, and topical preparations containing urea are effective against atopic eczema.
角化症、魚!/i徊等の治療薬として皮膚科領域で汎用
されている。Keratosis, fish! It is widely used in the field of dermatology as a therapeutic agent for conditions such as /i wandering.
(ロ)本発明が解決しようとする問題点尿素は水溶性の
化合物であるが、水溶液中で徐々に分解し、炭酸ガスと
アンモニアを生成する。(b) Problems to be Solved by the Present Invention Urea is a water-soluble compound, but it gradually decomposes in an aqueous solution to produce carbon dioxide gas and ammonia.
同様に尿素をクリームやゲル基剤に配合した場合にも尿
素は徐々に分解するため、クリーム或いはゲルが変質す
る。特に、チューブに充填した場合、保存条件によって
はチューブが膨張して内容物が飛びだしたり、ひどい場
合にはチューブが破裂して商品価値がなくなる場合があ
った。Similarly, when urea is added to a cream or gel base, urea gradually decomposes, resulting in deterioration of the quality of the cream or gel. In particular, when filled into a tube, depending on the storage conditions, the tube may expand and the contents may spill out, or in severe cases, the tube may burst and lose its commercial value.
特に、ゲル基剤の場合は通常水の配合量が多いため、尿
素の分解を抑えるのは困・′に「であった。In particular, since gel bases usually contain a large amount of water, it is difficult to suppress the decomposition of urea.
(ハ)従来の技術
尿素を含有するゲル製剤の先行技術としては、特公昭5
9−20217号公報に尿素の安定化剤としてアンモニ
ウム化合物を配合した例が開示されているが、この方法
でしても尿素の安定化は充分でなく、尿素の分解生成物
であるアンモニアうこよるpHの上界は抑えられていな
い。本発明の尿素を配合した透明ゲル製剤は特別な添加
物を配合することなしに尿素の安定性を達成することが
できたものであり、従来の尿素の安定化法とは全く別の
ものである。(c) Conventional technology The prior art of gel preparations containing urea is
9-20217 discloses an example in which an ammonium compound is blended as a stabilizer for urea, but even with this method, urea is not stabilized sufficiently, and ammonia, which is a decomposition product of urea, is The upper bound of pH is not suppressed. The transparent gel preparation containing urea of the present invention can achieve urea stability without adding special additives, and is completely different from conventional urea stabilization methods. be.
(ニ)問題点を解決するための手段
本発明者等は尿素を安定に保つゲル基剤について種々検
討した結果、カルボキシビニルポリマー。(d) Means for Solving the Problems The present inventors have conducted various studies on gel bases that keep urea stable, and as a result, they have developed carboxyvinyl polymer.
多価アルコール、pH調節剤及び水といった簡単な組合
せで尿素の安定化が達成できるということを見出し、本
発明を完成した。即ちゲル化剤としてカルボキシビニル
ポリマーを用い、水の配合量をできるだけ少なくし、代
わりに多量の多価アルコールを配合することによってゲ
ル基剤中の尿素の安定性を達成できた。The present invention was completed based on the discovery that stabilization of urea can be achieved with a simple combination of polyhydric alcohol, pH adjuster, and water. That is, by using a carboxyvinyl polymer as a gelling agent, minimizing the amount of water blended, and blending a large amount of polyhydric alcohol instead, stability of urea in the gel base could be achieved.
本発明のゲル基剤における尿素の安定化の作用機序は明
確ではないが、
fl)カルボキシビニルポリマーと塩基からなる塩が緩
衝剤となり、pHの上昇を抑える。Although the mechanism of action of stabilizing urea in the gel base of the present invention is not clear, fl) A salt consisting of a carboxyvinyl polymer and a base acts as a buffer and suppresses the increase in pH.
(2)水の代わりに多量配合している多価アルコールが
尿素の加水分解に対し抑制的に働く。(2) A large amount of polyhydric alcohol blended instead of water acts to suppress the hydrolysis of urea.
等の理由によるものと思われる。This seems to be due to the following reasons.
本発明のゲル製剤の有効成分である尿素の配合量は0.
5〜30重量%が好ましい。0.5重量%未満では尿素
の保湿作用が発揮されないし、また30重量%以上では
尿素の結晶が析出する等の問題が生じ製剤上好ましくな
い。本発明のゲル製剤の有効成分は尿素であるが、尿素
に加えてプロピオン酸クロベタゾール、吉草酸ベタメザ
ゾン、フルオシノニド等のステロイド系の抗炎症剤1イ
ンドメクシン、ケトプロフェン、フルルビプロフェン、
スルプロフェン、ロキソプロフエンナトリウム、イブプ
ロフェン、フェルビナク等の非ステロイド系の抗炎症剤
、或いはトルナフテート、クロトリマゾール等の抗菌剤
等を一緒に配合すると皮膚疾患治療剤として更に有用な
製剤となる。The amount of urea, which is an active ingredient in the gel preparation of the present invention, is 0.
5 to 30% by weight is preferred. If it is less than 0.5% by weight, the moisturizing effect of urea will not be exhibited, and if it is more than 30% by weight, problems such as precipitation of urea crystals will occur, which is not preferable in terms of formulation. The active ingredient of the gel preparation of the present invention is urea, and in addition to urea, steroidal anti-inflammatory agents such as clobetasol propionate, betamezazone valerate, fluocinonide, etc.1 indomexin, ketoprofen, flurbiprofen,
When combined with nonsteroidal anti-inflammatory agents such as sulprofen, loxoprofen sodium, ibuprofen, and felbinac, or antibacterial agents such as tolnaftate and clotrimazole, the formulation becomes even more useful as a therapeutic agent for skin diseases.
以下に本発明の基剤成分について更に詳細に説明する。The base component of the present invention will be explained in more detail below.
保湿剤として配合する多価アルコールとしてはプロピレ
ングリコール、グリセリン、ポリエチレングリコール、
■、3−ブチレングリコール、エチレングリコール1
ジエチレングリコール、トリエチレングリコール、ポリ
プロピレングリコール、ポリグリセリン、ソルビトール
水溶液等が用いられるが、皮膚刺激性の点からグリセリ
ンが最適である。これらの多価アルコールの配合量は2
5〜80重量%、好ましくは35〜55重量%が配合さ
れる。ゲル化剤として配合されるカルボキシビニルポリ
マーは、水溶性の高分子であり、例えばグッドリンチケ
ミカルズ社からカーボボール934.940.941或
いは和光純薬工業社からハイビス和光103.104゜
105等が商品化されており、処方に応じて選択される
。また、カルボキシビニルポリマーの配合量は、ゲル製
剤の物理的熱安定性、透明性、稠度及び使用感等の条件
を充分に考慮した配合量つまり0.1〜5重量%、好ま
しくは0.3〜1.5重量%配合される。Polyhydric alcohols used as moisturizers include propylene glycol, glycerin, polyethylene glycol,
■, 3-butylene glycol, ethylene glycol 1
Diethylene glycol, triethylene glycol, polypropylene glycol, polyglycerin, sorbitol aqueous solution, etc. are used, but glycerin is most suitable from the viewpoint of skin irritation. The amount of these polyhydric alcohols is 2
It is blended in an amount of 5 to 80% by weight, preferably 35 to 55% by weight. The carboxyvinyl polymer blended as a gelling agent is a water-soluble polymer, such as Carboball 934.940.941 from Goodlynch Chemicals or Hivis Wako 103.104°105 from Wako Pure Chemical Industries, Ltd. It is selected according to the prescription. In addition, the amount of carboxyvinyl polymer to be blended is 0.1 to 5% by weight, preferably 0.3% by weight, taking into full consideration conditions such as physical thermal stability, transparency, consistency, and feeling of use of the gel preparation. ~1.5% by weight is blended.
p II m1節剤としては、水酸化ナトリウム、水酸
化カリウム、アンモニア水等の無機塩基、トリエタノー
ルアミン、ジェタノールアミン、ジイソプロパツールア
ミン、トリイソプロパツールアミン。Examples of p II m1 moderators include inorganic bases such as sodium hydroxide, potassium hydroxide, and aqueous ammonia, triethanolamine, jetanolamine, diisopropanolamine, and triisopropanolamine.
アルギニン等の有機塩基が挙げられるが、有機塩基が特
に好ましい。Examples include organic bases such as arginine, and organic bases are particularly preferred.
これらのρII il!節剤の配合量は、ゲル調剤のp
l+が3〜9、好ましくは6〜8となるように0.02
〜3%の範囲で添加される。水の配合量は他の基剤に合
わせて適宜増減されるが、20〜70重星%、好ましく
は35〜55重量%配合するのがよい。These ρII il! The amount of moderation agent is based on the p of the gel preparation.
0.02 so that l+ is 3 to 9, preferably 6 to 8
It is added in a range of ~3%. The amount of water blended may be adjusted appropriately depending on the other base materials, but it is preferably 20 to 70% by weight, preferably 35 to 55% by weight.
また、上記の必須成分に加えて防腐剤、油状成分、抗酸
化剤等の補助成分を配合することができる。防腐剤とし
てはメチルパラベン、エチルパラベン、プロピルパラベ
ン、ブチルパラベン、チモール、クロルクレゾール、オ
ルトフェニルフェノール、イソプロピルメチルフェノー
ル、ピオニン等が通常用いられる濃度範囲で配合される
。油状成分は使用感を向上する目的で配合されるが、そ
れらの例としては、パルミチン酸イソプロピル。In addition to the above-mentioned essential ingredients, auxiliary ingredients such as preservatives, oily ingredients, and antioxidants may be added. As preservatives, methylparaben, ethylparaben, propylparaben, butylparaben, thymol, chlorcresol, ortho-phenylphenol, isopropylmethylphenol, pionin, etc. are blended in the concentration range commonly used. Oily components are added to improve the feeling of use, and an example of these is isopropyl palmitate.
ステアリン酸ブチル、ミリスチン酸イソプロピル。Butyl stearate, isopropyl myristate.
フタル酸ジエチル、乳酸ミリスチル、アジピン酸ジイソ
プロピル、ミリスチン酸セチル、乳酸セチル等のエステ
ル類、2−へキシルデカノール、オレイルアルコール、
2−オクチルドデカノール等の高級アルコール、スクワ
ラン、流動パラフィン等の炭化水素、ユーカリ油、ハツ
カ油、オリーブ油。Esters such as diethyl phthalate, myristyl lactate, diisopropyl adipate, cetyl myristate, cetyl lactate, 2-hexyldecanol, oleyl alcohol,
Higher alcohols such as 2-octyldodecanol, hydrocarbons such as squalane and liquid paraffin, eucalyptus oil, peppermint oil, and olive oil.
アボガド油、ホホバ油等の油脂、その他ベンジルアルコ
ール、フェニルエチルアルコール、クロタミトン等がゲ
ル製剤の透明性がなくならない濃度範囲で添加される。Fats and oils such as avocado oil and jojoba oil, as well as benzyl alcohol, phenylethyl alcohol, crotamiton, etc., are added in a concentration range that does not reduce the transparency of the gel preparation.
また抗酸化剤としては、ジブチルヒドロキシトルエン、
エリソルビン酸、d!−α−トコフェロール等が挙げら
れる。In addition, as an antioxidant, dibutylhydroxytoluene,
Erythorbic acid, d! -α-tocopherol and the like.
次に本発明のゲル製剤の製造方法について述べる。Next, the method for producing the gel preparation of the present invention will be described.
本発明の尿素を配合したゲル製剤を製造するには、まず
、カルボキシビニルポリマーを水に溶解し、これに多価
アルコールを加え攪拌した後、pH調節剤の水溶液を徐
々に加え均一になるまで攪拌する。次に尿素を溶解した
水溶液を加え、更に均一になるまで攪拌する。尚、上記
方法において製造工程の順序は特に限定されるものでは
なく、順序を一部いれかえても同様に製造することは可
能である。To produce the gel preparation containing urea of the present invention, first, carboxyvinyl polymer is dissolved in water, polyhydric alcohol is added thereto and stirred, and then an aqueous solution of a pH adjuster is gradually added until the mixture becomes uniform. Stir. Next, add an aqueous solution containing urea and stir until the mixture becomes uniform. Note that the order of the manufacturing steps in the above method is not particularly limited, and it is possible to manufacture the same in the same manner even if the order is partially changed.
以下に実施例及び試験例を示し、本発明を更に具体的に
説明する。EXAMPLES The present invention will be explained in more detail with reference to Examples and Test Examples below.
実施例!。Example! .
カルボキシビニルポリマー0.7gを水31gに加え撹
拌して溶解した。これにグリセリン42.6g及びメチ
ルパラベン0.2gを加え攪拌した。次に、これに水5
gにジイソプロパツールアミン
た溶液を加え攪拌した。次に、これに尿素10gを水L
ogに溶解した溶液を加え均一になるまで攪拌して尿素
配合の透明ゲル製剤を得た。0.7 g of carboxyvinyl polymer was added to 31 g of water and dissolved by stirring. 42.6 g of glycerin and 0.2 g of methylparaben were added to this and stirred. Next, add 5 liters of water to this
A solution of diisopropanolamine was added to g and stirred. Next, add 10g of urea to this and 1L of water.
A transparent gel preparation containing urea was obtained by adding the solution dissolved in OG and stirring until uniform.
実施例2。Example 2.
カルボキシビニルポリマー0.6gを水28gに加え攪
拌して溶解した。これにグリセリン45g及びメチルパ
ラベン0.2gを加え攪拌した。次にこれに水10gに
アルギニン1g,及びトリエタノールアミン0、2gを
溶解した溶液を加え攪拌した。次にこれに尿素10gを
水7gに溶解した溶液を加え均一になるまで攪拌して尿
素配合の透明ゲル製剤を得た。0.6 g of carboxyvinyl polymer was added to 28 g of water and dissolved by stirring. 45 g of glycerin and 0.2 g of methylparaben were added to this and stirred. Next, a solution of 1 g of arginine and 0.2 g of triethanolamine dissolved in 10 g of water was added and stirred. Next, a solution of 10 g of urea dissolved in 7 g of water was added to the mixture and stirred until it became uniform, to obtain a transparent gel preparation containing urea.
実施例3。Example 3.
カルボキシビニルポリマー0.8gを水16.6gに加
え攪拌して溶解した。これにグリセリン58g、プロピ
レングリコール2g1メチルパラベン0.2gJヒピオ
ニン0.002gを加え攪拌した。次にこれに水5gに
トリエタノールアミン0.5gを溶解した溶液を加え攪
拌した。次にこれに尿素logを水5gに溶解した溶液
を加え均一になるまで攪拌して尿素配合の透明ゲル製剤
を得た。0.8 g of carboxyvinyl polymer was added to 16.6 g of water and dissolved by stirring. To this were added 58 g of glycerin, 2 g of propylene glycol, 0.2 g of methylparaben, and 0.002 g of hypionine, and the mixture was stirred. Next, a solution of 0.5 g of triethanolamine dissolved in 5 g of water was added and stirred. Next, a solution of urea log dissolved in 5 g of water was added thereto and stirred until uniform, to obtain a transparent gel preparation containing urea.
実施例4。Example 4.
カルボキシビニルポリマー1gを水20gに加え攪拌し
て溶解した。これにグリセリン47g1メチルパラベン
0.15g 、プロピルパラベン0.03g及びセバシ
ン酸ジイソプロピルIgを加え攪拌した。次に、これに
1%水酸化ナトリウム溶液5gを加え撹拌した。次に、
これに尿素10gを水5.82gに溶解した溶液を加え
均一になるまで撹拌して尿素配合の透明ゲル製剤を得た
。1 g of carboxyvinyl polymer was added to 20 g of water and dissolved by stirring. To this were added 47 g of glycerin, 0.15 g of methylparaben, 0.03 g of propylparaben, and Ig of diisopropyl sebacate, and the mixture was stirred. Next, 5 g of 1% sodium hydroxide solution was added to this and stirred. next,
A solution of 10 g of urea dissolved in 5.82 g of water was added to this and stirred until uniform, to obtain a transparent gel preparation containing urea.
実施例5。Example 5.
カルボキシビニルポリマー0.7gを水27.13gに
加え撹拌して溶解した。これにグリセリン61g、メチ
ルパラベン0.13g 、プロピルパラベン0.05g
を加え攪拌した。次に、これにジイソプロパツールアミ
ン0.7gを水10gに溶解した溶液を加え均一になる
まで攪拌して透明ゲル基剤を得た。0.7 g of carboxyvinyl polymer was added to 27.13 g of water and dissolved by stirring. Add to this 61g of glycerin, 0.13g of methylparaben, 0.05g of propylparaben.
was added and stirred. Next, a solution of 0.7 g of diisopropanolamine dissolved in 10 g of water was added to this and stirred until uniform, to obtain a transparent gel base.
上記透明ゲル基剤に尿素10gを水20.に溶解した溶
液を加え均一になるまで攪拌して尿素配合の透明ゲル製
剤を得た。Add 10 g of urea to the above transparent gel base and 20 g of water. A transparent gel preparation containing urea was obtained by adding the solution dissolved in the solution and stirring until uniform.
実施例6。Example 6.
カルボキシビニルポリマー0.85gを水26.5gに
加え攪拌して溶解した。これにグリセリン50g、プロ
ピレングリコール2g、及びメチルパラベン0、 15
gを加え撹拌した。次に、これに水5gにトリエタノー
ルアミン0.6gを溶解した溶液を加え撹拌した1次に
、これに尿素5gを水10gに溶解した溶液を加え、均
一になるまで攪拌して尿素配合の透明ゲル製剤を得た。0.85 g of carboxyvinyl polymer was added to 26.5 g of water and dissolved by stirring. Add to this 50g of glycerin, 2g of propylene glycol, and 0.15 methylparaben.
g was added and stirred. Next, a solution of 0.6 g of triethanolamine dissolved in 5 g of water was added and stirred. Next, a solution of 5 g of urea dissolved in 10 g of water was added to this and stirred until it became uniform. A transparent gel formulation was obtained.
実脩例7゜
カルボキシビニルポリマー18を水20.4gに加え攪
拌して溶解した。これに1.3−ブチレンゲリコール4
5g及びメチルパラベン0.1gを加え攪拌した。Practical Example 7 Carboxyvinyl Polymer 18 was added to 20.4 g of water and stirred to dissolve. To this, 1,3-butylene gellicol 4
5 g and 0.1 g of methylparaben were added and stirred.
次に、これに水5gにトリイソプロパツールアミン0.
58をfJMした溶液を加え攪拌した0次に、これに尿
素15gを水13gに溶解した溶液を加え均一になるま
で攪拌して尿素配合の透明ゲル製剤を得た。Next, add 5 g of water and 0.0 g of triisopropanolamine.
Next, a solution of 15 g of urea dissolved in 13 g of water was added and stirred until the mixture became homogeneous to obtain a transparent gel preparation containing urea.
実施例8゜
カルボキシビニルポリマー1.5gを水27.13gに
加えR?i字して?8解した。これにグリセリン61g
1メチルパラベン0.13. 、プロピルパラベン0.
05g ’E:加え攪拌した0次に、これにトリエタノ
ールアミン0.7gを水10gに溶解した溶液を加え均
一になるまで攪拌して透明ゲル基剤を得た。この透明ゲ
ル基剤60gに尿素20gを水20gに溶解した溶液を
加え均一になるまで攪拌して尿素配合の透明ゲル製剤を
得た。Example 8 1.5g of carboxyvinyl polymer was added to 27.13g of water and R? I-character? I solved 8. Add this to 61g of glycerin
1 Methylparaben 0.13. , propylparaben 0.
05g 'E: Added and stirred 0 Next, a solution of 0.7g of triethanolamine dissolved in 10g of water was added thereto and stirred until homogeneous to obtain a transparent gel base. A solution of 20 g of urea dissolved in 20 g of water was added to 60 g of this transparent gel base and stirred until uniform, to obtain a transparent gel preparation containing urea.
参考例1゜
白色ワセリン25g1ステアリルアルコール20g、ポ
リオキシエチレン硬化ヒマシ油60.4g及びモノステ
アリン酸グリセリンIgをとり、水浴上で加熱して溶か
し、かき混ぜ、約75℃に保った。これにあらかじめメ
チルパラベン0.1g、及びプロピルパラベンO,1g
をプロピレングリコール12gに加工加温して溶かし水
27.8gに加えて75℃に加温した液を加え撹拌した
。これに攪拌しながら45℃まで冷却し、これに尿素1
0gを水10gに溶解した溶液を加え、更に攪拌を続は
クリーム状になるまで冷却し、尿素配合クリーム製剤を
得た。Reference Example 1 25 g of white vaseline, 20 g of stearyl alcohol, 60.4 g of polyoxyethylene hydrogenated castor oil, and Ig of glyceryl monostearate were heated on a water bath to dissolve, stir, and maintain at about 75°C. Add 0.1g of methylparaben and 1g of propylparaben O to this in advance.
was processed into 12 g of propylene glycol, heated, dissolved, added to 27.8 g of water, and the solution heated to 75° C. was added and stirred. This was cooled to 45°C while stirring, and urea was added to this.
A solution of 0 g dissolved in 10 g of water was added, and the mixture was further stirred and cooled until it became cream-like, to obtain a urea-containing cream preparation.
試験例!、(尿素の熱安定性試験)
実施例1.のゲル製剤、参考例1.のクリーム製剤及び
市販の尿素を10%含有するクリーム製剤について尿素
の熱安定性について検討した。Test example! , (Thermal stability test of urea) Example 1. Gel formulation of Reference Example 1. The thermal stability of urea was investigated for a cream formulation containing 10% of urea and a commercially available cream formulation containing 10% urea.
(試験方法)
10gチューブに充填した各製剤を40℃に保存し、経
時的に各製剤のρ11値を測定すると共に外観変化を観
察した。(Test method) Each formulation filled in a 10g tube was stored at 40°C, and the ρ11 value of each formulation was measured over time, and changes in appearance were observed.
表1の結果かられかるように、本発明の尿素含有のゲル
製剤は参考例1のクリーム製剤及び市販のクリーム製剤
に比べ尿素の安定性がよいため、pH値の変化が非常に
少なく、また、チューブの膨張もみられなかった。As can be seen from the results in Table 1, the urea-containing gel formulation of the present invention has better urea stability than the cream formulation of Reference Example 1 and commercially available cream formulations, so there is very little change in pH value. , no swelling of the tube was observed.
試験例2.(皮膚刺激性試験)
実施例1.のゲル製剤及び参考例1.のクリーム製剤に
ついて健康成人男子でのバッチテストを行った。Test example 2. (Skin irritation test) Example 1. Gel formulation and reference example 1. A batch test was conducted on healthy adult males for the cream formulation.
(試験方法)
健康成人男子の背部にFin chQmber 、 5
canportapeを用いて48時間クローズドバッ
チを行った。(Test method) Finch Qmber, 5 on the back of a healthy adult male.
A closed batch was run for 48 hours using camportape.
結果を表2に示した。The results are shown in Table 2.
判定:無反応(−)
僅かな紅斑(±)
明らかな紅斑(+)
紅斑+丘疹又は浮腫(科)
紅斑+丘疹、浮腫+小水庖(惜)
(ホ)発明の効果
本発明の尿素を含有するゲル製剤は、尿素を安定に含有
しているため、長期間保存しζも、pH値の変化が非常
に少なく、チューブ膨張等の外観変化が全くみられない
。又、カルボキシビニルポリマーをゲル化剤として配合
しているため、熱安定性がよく、経時的に粘度や稠度の
変化が非常に少ない。又、皮膚刺激性の強い基剤を配合
していないので、皮膚に対する刺激が非常に弱(、安全
性が高いという利点も有している。Judgment: No reaction (-) Slight erythema (±) Obvious erythema (+) Erythema + papules or edema (family) Erythema + papules, edema + small drops (e.g.) Effect of the invention The urea of the present invention Since the gel preparation contains urea stably, there is very little change in pH value even after long-term storage, and no changes in appearance such as tube swelling are observed. Furthermore, since carboxyvinyl polymer is blended as a gelling agent, it has good thermal stability and has very little change in viscosity or consistency over time. In addition, since it does not contain a base that is highly irritating to the skin, it has the advantage of being extremely safe and less irritating to the skin.
更に、優れた保湿性を有するため、角化症、魚Hm、ア
トピー性皮膚炎、老人性乾皮症等の治療剤として用いる
ことができる。その上、透明性に優れ、安定性がよく、
使用域がよいため化粧品、医薬部外品、或いは医薬品の
基剤としても応用することができる。特に、抗炎症剤や
抗菌剤を配合すると尿素が吸収促進剤或いは作用促進剤
として働くため更に有用である。Furthermore, since it has excellent moisturizing properties, it can be used as a therapeutic agent for keratosis, fish Hm, atopic dermatitis, senile xeroderma, etc. Moreover, it has excellent transparency and good stability.
Because of its wide range of uses, it can also be used as a base for cosmetics, quasi-drugs, and pharmaceuticals. In particular, it is more useful to incorporate an anti-inflammatory agent or an antibacterial agent because urea acts as an absorption enhancer or an action enhancer.
以上のことから、本発明のゲル製剤は化粧品、医薬部外
品、医薬品として、或いはそれらの基剤として産業上有
用な効果を有するものである。From the above, the gel preparation of the present invention has industrially useful effects as cosmetics, quasi-drugs, and pharmaceuticals, or as a base thereof.
Claims (1)
多価アルコール25〜80重量%、カルボキシビニルポ
リマー0.1〜5重量%、pH調節剤0.02〜3重量
%及び水20〜70重量%からなる透明ゲル製剤。0.5-30% by weight of urea as an active ingredient, 25-80% by weight of polyhydric alcohol as a base, 0.1-5% by weight of carboxyvinyl polymer, 0.02-3% by weight of pH adjuster, and 20-20% by weight of water. A transparent gel formulation consisting of 70% by weight.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP61314664A JPH0621061B2 (en) | 1986-12-27 | 1986-12-27 | Clear gel formulation containing urea stably |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP61314664A JPH0621061B2 (en) | 1986-12-27 | 1986-12-27 | Clear gel formulation containing urea stably |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS63166825A true JPS63166825A (en) | 1988-07-11 |
JPH0621061B2 JPH0621061B2 (en) | 1994-03-23 |
Family
ID=18056054
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP61314664A Expired - Lifetime JPH0621061B2 (en) | 1986-12-27 | 1986-12-27 | Clear gel formulation containing urea stably |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH0621061B2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001080850A1 (en) * | 2000-04-26 | 2001-11-01 | Kowa Co., Ltd. | Urea-containing gel preparation |
JP2003104877A (en) * | 2001-09-28 | 2003-04-09 | Isehan:Kk | Skin care preparation |
EP1683511A1 (en) * | 2005-01-13 | 2006-07-26 | Laboratoires S.V.R. | Squamous-regulating product containing urea and its cosmetologic application |
JP2009190986A (en) * | 2008-02-12 | 2009-08-27 | Kao Corp | Transparent gel cosmetic |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5920217A (en) * | 1982-07-27 | 1984-02-01 | Kawaken Fine Chem Co Ltd | Aqueous jellylike composition stably containing urea |
-
1986
- 1986-12-27 JP JP61314664A patent/JPH0621061B2/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5920217A (en) * | 1982-07-27 | 1984-02-01 | Kawaken Fine Chem Co Ltd | Aqueous jellylike composition stably containing urea |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001080850A1 (en) * | 2000-04-26 | 2001-11-01 | Kowa Co., Ltd. | Urea-containing gel preparation |
JP2003104877A (en) * | 2001-09-28 | 2003-04-09 | Isehan:Kk | Skin care preparation |
EP1683511A1 (en) * | 2005-01-13 | 2006-07-26 | Laboratoires S.V.R. | Squamous-regulating product containing urea and its cosmetologic application |
JP2009190986A (en) * | 2008-02-12 | 2009-08-27 | Kao Corp | Transparent gel cosmetic |
Also Published As
Publication number | Publication date |
---|---|
JPH0621061B2 (en) | 1994-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4178373A (en) | Coal tar gel composition | |
WO2020028820A1 (en) | Topical compositions and methods of preparation and use | |
US5225189A (en) | Minoxidil gel | |
KR20000049125A (en) | Local anesthetic for external use | |
JPS60209515A (en) | Anti-inflammatory and analgesic cream agent | |
JP2016145180A (en) | Liquid medicine for external use, and manufacturing method of liquid medicine for external use | |
JP3733546B2 (en) | Azulene aqueous liquid | |
JPS63166825A (en) | Clear gel drug preparation containing urea in stable state | |
WO2004030665A1 (en) | Transparent gel composition, for the administration of diclofenac sodium through the skin | |
JPS5869806A (en) | Cosmetic lotion containing stable collagen | |
JPH06192062A (en) | Dermal external preparation | |
JPH01143831A (en) | Solution for external use | |
JPS63270614A (en) | Clear gel base | |
JPS6219510A (en) | Cosmetic | |
JP3313148B2 (en) | External preparation for skin | |
JPS63297322A (en) | Production of stable ophthalmic solution containing sodium guaiazulenesulfonate | |
JPS61200918A (en) | Anti-inflammatory analgesic agent for external use | |
JPH0632710A (en) | Skin external preparation | |
JP2844132B2 (en) | Antibacterial cream preparation for external use on skin | |
JP2000007584A (en) | Solubilization of sparingly soluble medicament and composition of skin lotion | |
JPH0725674B2 (en) | Anti-inflammatory analgesic external cream preparation | |
JP3109623B2 (en) | Skin whitening agent | |
JPH0772133B2 (en) | Stable ketoprofen-containing cream formulation | |
EP0435180B1 (en) | Composition for treating hair | |
JP5109383B2 (en) | Adapalene-containing external preparation composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EXPY | Cancellation because of completion of term |